Young adults (N = 377, 22 31 yrs, 64.3% female) claiming disability benefits completed the RAND-36 and an online version of the HADS.
Thirty patients (46.9%) experienced stabilisation of disease, with a rate of overall clinical benefit (complete responses, partial responses, and stabilisation of disease) of 85.9%.
A clinical benefit (complete response, partial response or disease stabilization) was observed in 12 (80%) patients, 4 partial responses and 8 stable disease.
Group 1 consisted of patients who obtained a clinical benefit (complete response, partial response or stable disease) and remained on treatment.
In all, 73% of high EGFR GCN (⩾4.0) patients showed clinical benefit (complete response (CR)+partial response (PR)+stable disease (SD)) from anti-EGFR therapy, whereas only 20% of low EGFR GCN (<4.0) benefited from treatment.
The overall clinical response (complete response and partial response) was 55% (93 out of 168 evaluable patients) and clinical benefit (complete response, partial response and stable disease) was 75% (128 out of 168 evaluable patients).
In most trials there were significantly greater objective response rates (complete plus partial remissions) and/or rates of clinical benefit (complete plus partial remissions, and stable disease for 24 weeks or more) for AIs [ 9- 18] 18].
The primary objective of the study was to evaluate the study drugs in terms of clinical benefit (complete response (CR)+partial response (PR)+stabilisation of disease (SD) >6 months).
Due to the low rate of objective response (n = 4), analysis of potential predictive factors was carried out by categorizing patients as having either a clinical benefit (Complete response, CR; partial response, PR; and stable disease, SD; n = 15), or progressive disease (PD; n = 60), as previously described for this patient cohort [ 23].
